The GSEA also validated that tissues expressing high levels of CHRM4 were more likely to be positively associated with gene signatures involved in prostate cancer progression39–42, p53 mutation43, stemness44,45, NEPC differentiation25, and SCLC progression (KEGG) (Fig. 6i). Here, CHRM4 is linked to prostate carcinoma.